active psoriatic arthritis (PsA)

news

J&J’s Tremfya secures two paediatric psoriasis approvals from FDA

30 September 2025 | By Catherine Eckford (European Pharmaceutical Review)

The US FDA approvals make the drug the first IL-23 inhibitor to be licensed for two common skin conditions.

news

Early efficacy of arthritis therapy predicts long-term benefits

14 November 2022 | By Catherine Eckford (European Pharmaceutical Review)

Tremfya® trial analysis showing early skin and enthesitis response for active psoriatic arthritis could indicate long-term clinical response including disease remission.

news

AbbVie’s Skyrizi^® shows long-term efficacy in psoriatic arthritis

15 September 2022 | By Hannah Balfour (European Pharmaceutical Review)

Similar rates of skin improvement at week 100 indicate Skyrizi® (risankizumab) has consistent long-term efficacy in psoriatic arthritis patients.

news

Tremfya^® ranks highest for skin clearance in psoriatic arthritis patients

27 January 2022 | By European Pharmaceutical Review

Newly published Network Meta-Analysis (NMA) from Janssen indirectly compares all published Phase III data for approved treatments for adults with active Psoriatic Arthritis (PsA).

news

Data shows long-term efficacy of Tremfya^® in active psoriatic arthritis

17 March 2021 | By Hannah Balfour (European Pharmaceutical Review)

The joint and skin response rates of adults with active psoriatic arthritis observed with Tremfya® (guselkumab) were maintained over two years.

news

EC approves RINVOQ (upadacitinib) to treat active psoriatic arthritis

26 January 2021 | By Victoria Rees (European Pharmaceutical Review)

AbbVie's RINVOQ (upadacitinib) has been approved in the EU to treat adult patients with active psoriatic arthritis (PsA).